Focus Areas

Targeted TherapiesTransforming Cancer Care Across Multiple Fronts

Breast Cancer
Targeting aggressive forms of breast cancer with high ALDH1A3 expression to reduce metastasis and improve survival outcomes.
Lung Cancer
Addressing chemotherapy-resistant non-small cell lung cancers by inhibiting ALDH1A3-driven tumor progression.
Colorectal Cancer
Offering precision therapies to patients with advanced colorectal cancer, focusing on reducing recurrence rates.
Prostate Cancer
Tackling metastatic prostate cancer through ALDH1A3 inhibition to enhance treatment efficacy and reduce drug resistance.
Glioblastoma
Developing innovative treatments for this aggressive brain cancer, with a focus on limiting tumor growth and improving quality of life.
Pancreatic Cancer
Aiming to provide new therapeutic options for one of the most challenging cancers to treat due to its resistance to conventional therapies.
Combination Therapy
Enhancing the effectiveness of standard-of-care treatments by integrating ALDH1A3 inhibitors for synergistic outcomes.

Get In TouchConnect with Us Today

Have questions about our groundbreaking cancer therapies or partnership opportunities? Reach out to Theranib Inc. and join us in advancing cancer care worldwide.

Our Location

Halifax: 1300 – 1969 Upper Water Street, McInnes Cooper Tower, Halifax NS B3J 3R7

Email

info@theranib.com 

Social network

Coming Soon

Get in Touch

Please enable JavaScript in your browser to complete this form.